It is noteworthy that despite mutations in the IL12/IFNγ pathway causing susceptibility to DCM (reviewed in Odio [45]), there have been no reports of patients receiving ustekinumab (IL-12/IL-23 monoclonal antibody) developing coccidioidomycosis; nor have there been reports of patients receiving monoclonal biologics against IL-6 (tocilizumab) or JAK1/JAK3 (tofacitinib). This evidence concerns the gene JAK1 and coccidioidomycosis.